RAILY AESMED (02135) and Suneva entered into a supply agreement.

RAILY AESMED (02135) announces that on January 24, 2024, the company entered into a supply agreement with Suneva, under which the company will acquire distribution rights and equity. The announcement states that the group's main business is to provide medical beauty services. Suneva owns or controls several proprietary intellectual properties related to Belifill. The acquisition of distribution rights aims to ensure that Suneva supplies Belifill to the group within the term of the supply agreement and grants the group exclusive distribution rights for Belifill in Greater China. The acquisition of equity will strengthen the long-term cooperation between the group and Suneva. Therefore, the group plans to expand its supply chain in the medical beauty services industry through the acquisition and secure a stable and reliable supply of Belifill. The directors believe that the acquisition will enhance the group's business operations and strengthen the supply of Belifill for sale in Greater China. Due to unintentional negligence by the management, the company did not make a declaration or announcement regarding the acquisition. Therefore, the acquisition did not comply with the provisions of Chapter 14 of the Listing Rules. The company acknowledges that the unintentional violation of the Listing Rules was due to negligence and reiterates its belief that continued compliance with the Listing Rules and other applicable regulatory requirements is crucial. The responsible personnel should obtain necessary approvals and/or consent before entering into any agreements that may constitute transactions requiring disclosure by the company in the future.